Skip to main content
Menu

Case Studies

Enabling Global Participation in a Rare Disease Hybrid Study for Cerebral Adrenoleukodystrophy (CALD)

Study Snapshot

  • Client: Global biopharmaceutical sponsor
  • Study: Rare disease hybrid study for cerebral adrenoleukodystrophy (CALD)
  • Service(s): Patient Travel, Patient Payments & Decentralized Clinical Services
  • Study Model: Hybrid delivery across site and home
  • Patient Countries: Russia, Albania, Malaysia, Australia, China, Europe, Latin America & the United States
  • Global Compliance: GDPR, HIPAA, MR001 & regional privacy regulations
  • In-Home Care: Local nurses and physicians delivering protocol visits where travel was not possible
  • Global Patient Support: Coordinated travel, reimbursements and in-home clinical care across multiple regions.

Study Overview

Cerebral adrenoleukodystrophy (CALD) is a rare and devastating form of X-linked adrenoleukodystrophy (ALD), a genetic disorder that prevents the body from breaking down very-long-chain fatty acids (VLCFAs). The resulting buildup causes progressive damage to the brain’s white matter and adrenal glands. In adults, CALD progresses rapidly and, without treatment, can lead to severe neurological decline, a vegetative state or death within three to four years of symptom onset.

A global biopharmaceutical sponsor partnered with mdgroup to support a hybrid rare disease clinical trial, bringing together participants from around the world to evaluate a potential treatment for CALD. To support global participation, mdgroup delivered Patient Travel, Patient Payments and Decentralized Clinical Services. Together, these services enabled patients to access specialist research sites while reducing the burden of participation through coordinated travel, reimbursements and in-home clinical care.

The Challenge

Recruiting sufficient participants for a rare disease study required a truly global approach, with patients travelling from countries including Russia, Albania, Malaysia, Australia, China and the United States, as well as across Europe and Latin America.

Delivering a global hybrid study for a rare disease population presented several operational challenges:

  • Patients required ambulance transport and caregiver support to attend research sites.
  • International travel and reimbursement arrangements had to be coordinated across multiple regions.
  • Home-based protocol visits. Some protocol visits needed to be delivered by qualified nurses and physicians in patients’ home countries.
  • Global privacy compliance. The study required compliance with multiple international privacy regulations, including GDPR, HIPAA and regional data protection requirements.

The Solution

mdgroup designed and delivered a fully integrated patient support program combining Patient Travel, Patient Payments and Decentralized Clinical Services to remove logistical, financial and regulatory barriers while maintaining the highest standards of compliance and patient care.

International and domestic travel was coordinated end-to-end, including flights, accessible ground transportation, visa assistance and accommodation tailored to each patient’s medical and personal needs. Where required, specialist transport and caregiver arrangements were provided to ensure patients could travel safely and comfortably to research sites.

To reduce the financial burden on families, mdgroup implemented transparent, compliant reimbursement processes aligned with local and regional regulations, creating an auditable framework for managing travel and living expenses throughout the study.

For patients unable to travel, mdgroup partnered with trusted local nursing networks to deliver protocol-required clinical procedures in the home. Qualified healthcare professionals carried out visits in accordance with study requirements, ensuring continuity of care while maintaining protocol adherence and data quality.

Throughout the study, privacy and regulatory compliance remained central to delivery. A robust cross-border data protection framework ensured compliance with GDPR, HIPAA, MR001 and other regional regulations, while multilingual interpreters and translated study materials supported clear communication and culturally appropriate engagement with patients and families across diverse geographies.

By combining global logistics, financial support and home-based clinical services, mdgroup enabled patients to participate in the study with confidence, regardless of where they lived, while reducing burden for both families and research sites.

The Results

Through this integrated, patient-first approach, mdgroup successfully supported global recruitment and retention while minimizing barriers to participation. The program led to increased patient enrollment and sustained engagement across multiple regions, while significantly reducing logistical and financial burdens for CALD participants and their caregivers. Throughout the study, mdgroup maintained full compliance with international privacy and data protection laws and delivered a culturally sensitive, compassionate experience that prioritized the comfort and confidence of every patient involved.

The Impact

For the Sponsor

By removing logistical and financial barriers to participation, mdgroup helped improve patient recruitment and retention while reducing operational complexity. Full compliance with international privacy regulations minimized regulatory risk, and streamlined processes reduced the administrative burden on study teams, supporting the successful delivery of this global hybrid trial.

For Sites & Healthcare Professionals

Site teams benefited from improved protocol compliance, fewer missed appointments and clearer communication through multilingual, culturally sensitive patient support. With travel coordination, reimbursements and home-based clinical services managed by mdgroup, healthcare professionals were able to focus on delivering high-quality clinical care.

For Patients & Families

Comprehensive travel, reimbursement and in-home clinical support removed barriers to participation and reduced the burden of taking part in the study. Home nursing visits ensured continuity of care, while transparent consent processes and secure data handling gave patients and families confidence throughout their clinical trial journey.

By combining global reach, cultural intelligence and technology-enabled compliance, mdgroup delivered a hybrid support model that made participation in this rare disease study both possible and empowering for patients worldwide.

This project demonstrates mdgroup’s ongoing commitment to delivering patient-driven clinical solutions that make clinical trials more accessible, more efficient and more human—no matter how complex the challenge.

 

Ready to Simplify Your Next Clinical Trial?

Whether you’re planning a rare disease study, decentralized trial or global research program, mdgroup can help reduce patient burden and deliver the support your study needs to succeed.

Get in touch today to discuss how our patient support solutions can help your next clinical trial.

 

Tags: